All stars🇮🇹Uro-radoncs together in Milan : @GiuliaMarvaso84 @StAr_MCM74 #giuliofrancolini #cirofranzese .Grateful to #Ipsen for the opportunity to be scientific coordinator of such a stimulating and multidisciplinary event on prostate cancer also with urologists and oncologists!

🚀 POPART trial (n=100): Post-op SABR (32.5 Gy/5fx) for BCR after prostatectomy ✅ well-tolerated; late ≥G2 GU 7.5%, GI 1% 📉 2-yr BRFS ~79% (PSA ↓ to 0.028 ng/mL) ➡️SBRT prostate bed salvage = promising, needs longer follow-up. #ASTRO25 #RadOnc @ASTRO_org

#UroOncoJourney2025 🇮🇹 The multidisciplinary debate on #RCC is always heated 🔥 even more so if the best ( @CPRT65,@CiroFranzese1, Andrea Minervini) take the field, expertly arbitrated by @DrIacovelli. However, the goal can only be achieved together!! 🥅 @urofocus @AntureIT

🎩🎩 off to 🇮🇹 @GiulioFrancoli1 @GiuliaMarvaso84 and @CiroFranzese1 for handling the GU sessions #ESTRO25 so well, either as chairs or speakers ⚡️so inspiring for the younger colleagues 🤩 #ProstateCancer #radonc @ESTRO_RT

SBRT + 💊 in oligomets: 🧍‍♂️2294 pts | 🫁, breast, prostate, colorectal ⚠️Grade 3+ AEs: 1.5% ✅ SBRT Safe with systemic tx! #SBRT #OligoCare #ESTRO25 @EORTC @ESTRO_RT @CiroFranzese1

Hot of the press @IJROBP: Role of SABR in oligometastatic head and neck cancer: a GORTEC randomized trial Full text here: https://t.co/MuEI1uURxQ

Fantastic roundtable on renal & prostate #SBRT with @CiroFranzese1 🇮🇹 & @DrMedo58935306 🇨🇭 ! ✅ Growing evidence for renal SBRT with excellent local control ✅ Comparisons of SBRT regimens even in 1-2 sessions! Many thanks for your participation!

#GU25 highlights #CommunityOnc: 1. Radical ✂️ vs. XRT high risk PCa 2. #TALAPRO2: PARPi in M1 CRPC 3. #EnzaP: ARPi + LuPSMA in M1 CRPC 4. #NIAGARA update: Resectable MIBC 5. #EV302 update: Metastatic #BladderCancer 6. #CM9ER update: 1L mRCC #OncTwitter #gism @ASCO 1/7

A 33 min overview of GI rad onc! I made this video for an oral boards review course, sharing here. It’s just 5 slides (below) & me talking the whole time, so you can just listen. Hope it’s helpful! Link next post, and short 🧵.

📢🚨 Hot off the press @TheLancetOncol for #kidneycancer! https://t.co/v4fXO17tLp. SABR vs thermal ablation; - Despite ⏫age, ⏬worse GFR, and ⏫tumours for SABR - SABR ⬆️effective than TA (at 1, 2 and 5 yrs) - esp for RCC >4cm - same renal decline (p=0.75) - similar F/U #radonc

-This large series of primary RCC treated with SBRT demonstrates excellent LC and renal function preservation. -SBRT is an alternative treatment for inoperable patients. 💪 @_ShankarSiva @David__Pasquier @CiroFranzese1 @NicosiaMd @MartaScorsetti 👉 https://t.co/BygkP3KXgL

Joining forces against kidney cancer! Published a new international multicenter study on SBRT for renal cell carcinoma SBRT is a valuable option with: ✅ 96% local control at 5 years ✅ Good preservation of renal function ✅ Acceptable toxicity profile with only 1% of G ≥3

Very sad day for Americans and the world, a calamity: Trump orders US to leave World Health Organization

🚨 The 2024 FROGG Guidelines for Post-Prostatectomy Radiation Therapy (PPRT) are here, bringing groundbreaking updates backed the by the latest evidence❗️@OncoAlert 🧵1/7

SPOTLIGHT: Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial by @nickva1 Read the full article here: https://t.co/Q7kqBXvy0h #UroSoMe #MedTwitter #eururol #EditorsChoice #spotlight

It's that time of the year when we need to slow down and return to our roots, to our family and loved ones. And that's exactly what we're doing. We wish everyone a Merry Christmas and a wonderful 2025! (Yes, we're stuck in traffic!!!)

Radical cystectomy (RC) and trimodality therapy (TMT) yield comparable outcomes in muscle-invasive bladder cancer (MIBC)? ✨ 74.4% complete response with TMT. 🔄 23.1% recurrence rate in TMT-treated patients. ⚠️ 11.4% grade ≥3 toxicity for TMT. Does this change your practice?

PEACE-1 RT is now published online at @TheLancet Some differences with STAMPEDE Key messages: RT to prostate in M1 #prostatecancer 1. improves rPFS but not OS in low volume 2. improves CRPC-FS & reduces serious GU SAE irrespective of volume Full text: https://t.co/bfPzTdWTro

"Oligo"-no more! 🇨🇦ARREST phase I out now @IJROBP - @sueyom ➡️SABR to median=16 "poly"metastases in patients who had already exhausted multiple lines of systemic therapy ➡️4x dose levels (up to 6Gyx5). ➡️No safety signals, QoL maintained. https://t.co/ZIjhtg6RCJ Congrats! 👏👏

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial, published in @JAMAOnc. 👉 Read it before your patients: https://t.co/eXs6tYYrdb